Sera Prognostics (SERA)
NASDAQ:SERA
Want to see SERA full AI Analyst Report?
SERA Stock Chart & Stats
$2.30
$0.42(5.34%)
At close: 4:00 PM EST
$2.30
$0.42(5.34%)
Day’s Range― - ―
52-Week Range$1.37 - $4.09
Previous CloseN/A
Volume57.63K
Average Volume (3M)40.22K
Market Cap
$84.58M
Enterprise Value$80.82M
Total Cash (Recent Filing)$47.40M
Total Debt (Recent Filing)$2.50M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Aug 12, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding38,190,968
10 Day Avg. Volume55,279
30 Day Avg. Volume40,220
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.86
Price to Sales (P/S)1735.84
P/FCF Ratio-5.34
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue1.42K
Enterprise Value/Gross Profit-741.49
Enterprise Value/Ebitda-2.50
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.67
Revenue Forecast (FY)$466.67K
Bulls Say, Bears Say
Bulls Say
Clinical ValidationFormal publication of the PRIME study in a peer-reviewed medical journal validates clinical evidence for the PreTRM test and strengthens commercial discussions with payers and providers.
Payer EngagementBroader payer engagement and targeted partner programs across Medicaid and commercial plans can increase access and coverage for the PreTRM test, supporting higher test utilization.
Valuation OpportunityMarket valuation below reported cash presents an attractive risk/reward profile that may draw investor interest if commercial milestones progress.
Bears Say
Catalyst ScarcityAn uneventful corporate update with few new catalysts could limit stock momentum and reduce investor interest.
Commercial Execution RiskLimited sales resources and a small commercial team increase the risk of constrained execution and slower customer base expansion.
Product Concentration And Pipeline RiskDependence on a single commercial test and an unproven pipeline beyond the initial offering raise revenue concentration and long-term growth concerns.
Sera Prognostics News
SERA FAQ
What was Sera Prognostics’s price range in the past 12 months?
Sera Prognostics lowest stock price was $1.37 and its highest was $4.09 in the past 12 months.
What is Sera Prognostics’s market cap?
Sera Prognostics’s market cap is $84.58M.
When is Sera Prognostics’s upcoming earnings report date?
Sera Prognostics’s upcoming earnings report date is Aug 12, 2026 which is in 73 days.
How were Sera Prognostics’s earnings last quarter?
Sera Prognostics released its earnings results on May 06, 2026. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.167 by -$0.003.
Is Sera Prognostics overvalued?
According to Wall Street analysts Sera Prognostics’s price is currently Overvalued.
Does Sera Prognostics pay dividends?
Sera Prognostics does not currently pay dividends.
What is Sera Prognostics’s EPS estimate?
Sera Prognostics’s EPS estimate is -0.15.
How many shares outstanding does Sera Prognostics have?
Sera Prognostics has 38,190,968 shares outstanding.
What happened to Sera Prognostics’s price movement after its last earnings report?
Sera Prognostics reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.167. Following the earnings report the stock price went up 6.077%.
Which hedge fund is a major shareholder of Sera Prognostics?
Currently, no hedge funds are holding shares in SERA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sera Prognostics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Neutral
SERA Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $96.1K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-58.89%
12-Months-Change
Fundamentals
Return on Equity
-41.02%
Trailing 12-Months
Asset Growth
-20.85%
Trailing 12-Months
Company Description
Sera Prognostics
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
SERA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed picture: strong strategic progress on commercialization, payer engagement, media awareness, scientific publications and a clear plan to reduce operating expense that together support a multi-year commercial opportunity. However, near-term financials remain weak — Q1 revenue fell to $14k (down ~63% YoY), a continuing net loss (~$8.4M) and management expects 2026 revenue to be modest and uneven while payer coverage and broader adoption timelines play out. Given meaningful operational and evidence milestones but limited near-term revenue visibility, the tone is cautiously constructive but balanced by financial and timing risks.View all SERA earnings summariesSERA Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Ownership Overview
7.75% Insiders
4.06% Mutual Funds
36.09% Other Institutional Investors
48.75% Public Companies and
Individual Investors